Phase II study of PS341 (VELCADE [bortezomib]) in myelodysplastic syndromes (MDS). EudraCT Number 2004-002935-23
Phase of Trial: Phase II
Latest Information Update: 09 Jun 2015
At a glance
- Drugs Bortezomib (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 09 Nov 2008 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 09 Nov 2008 Planned end date changed to 1 Mar 2008 as reported by ClinicalTrials.gov.
- 10 Apr 2007 New trial record.